HIF1A and myeloid sarcoma: Given the association between hypoxia and MS pathogenesis, it is tempting to speculate that regulating HIF-1α may be possible to improve the local hypoxic microenvironment in MS patients, reducing vascular inflammation and fibrosis, and ultimately alleviating clinical symptoms.